Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Drugs for Solid Tumors market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Drugs for Solid Tumorsmarket, defines the market attractiveness level of Drugs for Solid Tumors market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Drugs for Solid Tumors industry, describes the types of Drugs for Solid Tumors market, the applications of major players and the market size, and deeply analyzes the current situation of the global Drugs for Solid Tumors market and the development prospects and opportunities of Drugs for Solid Tumors industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Drugs for Solid Tumors market in Chapter 13.
By Player:
Boston Biomedical
BMS
Pfizer
Eli Lilly
GSK
Hoffmann-La Roche
AstraZeneca
Johnson & Johnson
Daiichi Sankyo
Bayer
Celgene
AbbVie
Novartis
Biogen
Sanofi
Boehringer Ingelheim
Merck
By Type:
Small Molecules
Biologics
By End-User:
Hospitals
Clinics
Academic and Research Institutes
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Drugs for Solid Tumors Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Drugs for Solid Tumors Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Drugs for Solid Tumors Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Drugs for Solid Tumors Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Drugs for Solid Tumors Market Analysis and Outlook to 2022
-
7.1 Global Drugs for Solid Tumors Consumption (2017-2022)
-
7.2 United States Drugs for Solid Tumors Consumption (2017-2022)
-
7.3 Europe Drugs for Solid Tumors Consumption (2017-2022)
-
7.4 China Drugs for Solid Tumors Consumption (2017-2022)
-
7.5 Japan Drugs for Solid Tumors Consumption (2017-2022)
-
7.6 India Drugs for Solid Tumors Consumption (2017-2022)
-
7.7 South Korea Drugs for Solid Tumors Consumption (2017-2022)
8 Region and Country-wise Drugs for Solid Tumors Market Analysis and Outlook to 2028
-
8.1 Global Drugs for Solid Tumors Consumption Forecast (2022-2028)
-
8.2 United States Drugs for Solid Tumors Consumption Forecast (2022-2028)
-
8.3 Europe Drugs for Solid Tumors Consumption Forecast (2022-2028)
-
8.4 China Drugs for Solid Tumors Consumption Forecast (2022-2028)
-
8.5 Japan Drugs for Solid Tumors Consumption Forecast (2022-2028)
-
8.6 India Drugs for Solid Tumors Consumption Forecast (2022-2028)
-
8.7 South Korea Drugs for Solid Tumors Consumption Forecast (2022-2028)
9 Global Drugs for Solid Tumors Market Outlook by Types and Applications to 2022
-
9.1 Global Drugs for Solid Tumors Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Small Molecules Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Biologics Consumption and Growth Rate (2017-2022)
-
9.2 Global Drugs for Solid Tumors Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Academic and Research Institutes Consumption and Growth Rate (2017-2022)
10 Global Drugs for Solid Tumors Market Outlook by Types and Applications to 2028
-
10.1 Global Drugs for Solid Tumors Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Small Molecules Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Biologics Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Drugs for Solid Tumors Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Academic and Research Institutes Consumption Forecast and Growth Rate (2022-2028)
11 Global Drugs for Solid Tumors Import and Export Analysis (Top 5 Countries)
-
11.1 Global Drugs for Solid Tumors Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Drugs for Solid Tumors Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Drugs for Solid Tumors Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Drugs for Solid Tumors Market Competitive Analysis
-
14.1 Boston Biomedical
-
14.1.1 Boston Biomedical Company Details
-
14.1.2 Boston Biomedical Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Boston Biomedical Drugs for Solid Tumors Product and Service
-
14.2 BMS
-
14.2.1 BMS Company Details
-
14.2.2 BMS Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 BMS Drugs for Solid Tumors Product and Service
-
14.3 Pfizer
-
14.3.1 Pfizer Company Details
-
14.3.2 Pfizer Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Pfizer Drugs for Solid Tumors Product and Service
-
14.4 Eli Lilly
-
14.4.1 Eli Lilly Company Details
-
14.4.2 Eli Lilly Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Eli Lilly Drugs for Solid Tumors Product and Service
-
14.5 GSK
-
14.5.1 GSK Company Details
-
14.5.2 GSK Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 GSK Drugs for Solid Tumors Product and Service
-
14.6 Hoffmann-La Roche
-
14.6.1 Hoffmann-La Roche Company Details
-
14.6.2 Hoffmann-La Roche Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Hoffmann-La Roche Drugs for Solid Tumors Product and Service
-
14.7 AstraZeneca
-
14.7.1 AstraZeneca Company Details
-
14.7.2 AstraZeneca Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 AstraZeneca Drugs for Solid Tumors Product and Service
-
14.8 Johnson & Johnson
-
14.8.1 Johnson & Johnson Company Details
-
14.8.2 Johnson & Johnson Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Johnson & Johnson Drugs for Solid Tumors Product and Service
-
14.9 Daiichi Sankyo
-
14.9.1 Daiichi Sankyo Company Details
-
14.9.2 Daiichi Sankyo Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Daiichi Sankyo Drugs for Solid Tumors Product and Service
-
14.10 Bayer
-
14.10.1 Bayer Company Details
-
14.10.2 Bayer Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 Bayer Drugs for Solid Tumors Product and Service
-
14.11 Celgene
-
14.11.1 Celgene Company Details
-
14.11.2 Celgene Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.11.3 Celgene Drugs for Solid Tumors Product and Service
-
14.12 AbbVie
-
14.12.1 AbbVie Company Details
-
14.12.2 AbbVie Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.12.3 AbbVie Drugs for Solid Tumors Product and Service
-
14.13 Novartis
-
14.13.1 Novartis Company Details
-
14.13.2 Novartis Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.13.3 Novartis Drugs for Solid Tumors Product and Service
-
14.14 Biogen
-
14.14.1 Biogen Company Details
-
14.14.2 Biogen Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.14.3 Biogen Drugs for Solid Tumors Product and Service
-
14.15 Sanofi
-
14.15.1 Sanofi Company Details
-
14.15.2 Sanofi Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.15.3 Sanofi Drugs for Solid Tumors Product and Service
-
14.16 Boehringer Ingelheim
-
14.16.1 Boehringer Ingelheim Company Details
-
14.16.2 Boehringer Ingelheim Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.16.3 Boehringer Ingelheim Drugs for Solid Tumors Product and Service
-
14.17 Merck
-
14.17.1 Merck Company Details
-
14.17.2 Merck Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
14.17.3 Merck Drugs for Solid Tumors Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Drugs for Solid Tumors
-
Figure Drugs for Solid Tumors Picture
-
Table Global Drugs for Solid Tumors Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Drugs for Solid Tumors Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Drugs for Solid Tumors Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Drugs for Solid Tumors Consumption by Country (2017-2022)
-
Figure United States Drugs for Solid Tumors Consumption and Growth Rate (2017-2022)
-
Table Europe Drugs for Solid Tumors Consumption and Growth Rate (2017-2022)
-
Figure China Drugs for Solid Tumors Consumption and Growth Rate (2017-2022)
-
Figure Japan Drugs for Solid Tumors Consumption and Growth Rate (2017-2022)
-
Figure India Drugs for Solid Tumors Consumption and Growth Rate (2017-2022)
-
Figure South Korea Drugs for Solid Tumors Consumption and Growth Rate (2017-2022)
-
Figure Global Drugs for Solid Tumors Consumption Forecast by Country (2022-2028)
-
Figure United States Drugs for Solid Tumors Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Drugs for Solid Tumors Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Drugs for Solid Tumors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Drugs for Solid Tumors Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Drugs for Solid Tumors Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Drugs for Solid Tumors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Small Molecules Consumption and Growth Rate (2017-2022)
-
Figure Global Biologics Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Academic and Research Institutes Consumption and Growth Rate (2017-2022)
-
Figure Global Small Molecules Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Biologics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Academic and Research Institutes Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Drugs for Solid Tumors Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Drugs for Solid Tumors Export by Region (Top 5 Countries) (2017-2028)
-
Table Boston Biomedical (Foundation Year, Company Profile and etc.)
-
Table Boston Biomedical Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boston Biomedical Drugs for Solid Tumors Product and Service
-
Table BMS (Foundation Year, Company Profile and etc.)
-
Table BMS Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table BMS Drugs for Solid Tumors Product and Service
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Drugs for Solid Tumors Product and Service
-
Table Eli Lilly (Foundation Year, Company Profile and etc.)
-
Table Eli Lilly Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly Drugs for Solid Tumors Product and Service
-
Table GSK (Foundation Year, Company Profile and etc.)
-
Table GSK Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table GSK Drugs for Solid Tumors Product and Service
-
Table Hoffmann-La Roche (Foundation Year, Company Profile and etc.)
-
Table Hoffmann-La Roche Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Hoffmann-La Roche Drugs for Solid Tumors Product and Service
-
Table AstraZeneca (Foundation Year, Company Profile and etc.)
-
Table AstraZeneca Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Drugs for Solid Tumors Product and Service
-
Table Johnson & Johnson (Foundation Year, Company Profile and etc.)
-
Table Johnson & Johnson Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Johnson & Johnson Drugs for Solid Tumors Product and Service
-
Table Daiichi Sankyo (Foundation Year, Company Profile and etc.)
-
Table Daiichi Sankyo Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Daiichi Sankyo Drugs for Solid Tumors Product and Service
-
Table Bayer (Foundation Year, Company Profile and etc.)
-
Table Bayer Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer Drugs for Solid Tumors Product and Service
-
Table Celgene (Foundation Year, Company Profile and etc.)
-
Table Celgene Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celgene Drugs for Solid Tumors Product and Service
-
Table AbbVie (Foundation Year, Company Profile and etc.)
-
Table AbbVie Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table AbbVie Drugs for Solid Tumors Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Drugs for Solid Tumors Product and Service
-
Table Biogen (Foundation Year, Company Profile and etc.)
-
Table Biogen Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biogen Drugs for Solid Tumors Product and Service
-
Table Sanofi (Foundation Year, Company Profile and etc.)
-
Table Sanofi Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Drugs for Solid Tumors Product and Service
-
Table Boehringer Ingelheim (Foundation Year, Company Profile and etc.)
-
Table Boehringer Ingelheim Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim Drugs for Solid Tumors Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck Drugs for Solid Tumors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Drugs for Solid Tumors Product and Service
-
